TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Child up to 15 years of age who fulfilled the 1997 updating the American College of Rheumatology revised criteria for the classification of SLE and his or her renal biopsy reveals lupus nephritis class III or IV regarding to International Society of Nephrology/Renal Pathology Society revision on the classification of the lupus nephritis.~Exclusion Criteria:~* patient who has prior renal insufficiency due to chronic kidney disease other than lupus nephritis~* patient who has the history of cyclophosphamide hypersensitivity~* patient who has prior cyclophosphamide or mycophenolate mofetil administration within 6 months~* patient who is pregnant

- Gender: ALL
- Minimum Age: None
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Low-dose intravenous cyclophosphamide (Type: EXPERIMENTAL): Low-dose intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months for 7 doses. Total duration is 6 months for the induction treatment.
- High-dose intravenous cyclophosphamide (Type: ACTIVE_COMPARATOR): High-dose intravenous cyclophosphamide 1,000 mg/m2/dose, the first dose will be started with 500 mg/m2/dose and steped up to 750 mg/m2/dose for the second dose. Then the dosage will be increased to 1,000 mg/m2/dose for the third dose and continued the dosage through the seventh dose. Total duration is 6 months for the induction treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tryptophan Depletion in PD Patients Treated With STN DBS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* subjects must be mentally competent~* subjects must have undergone STN DBS surgery for PD symptomatology~Exclusion Criteria:~* head injury~* stroke~* currentl malignancy or infection~* neurological disorders other than PD~* psychoactive medication: specifically antidepressants and antipsychotics ( a stable dose of benzodiazepines will be allowed)~* clinically relevant cognitive decline, operationalized as a MMSE score \< 24~* current psychiatric syptomatology, operationalized as a Hamilton Depression scale score \> 16 or a score \>2 on one of the MDS-UPDRS section I, items 1-6

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TRP depleted (Type: EXPERIMENTAL): TRP depleted protein drink
- Placebo (Type: PLACEBO_COMPARATOR): Balanced protein drink (+1.21g of TRP)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with recurrent or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)~* Prior treatment with at least 2 systemic chemotherapy regimens for CLL~* Life expectancy of \>3 months~* Adequate liver and kidney function~* Absolute neutrophil count ≥500/mm3; platelets ≥50,000/dL; hemoglobin ≥9 g/dL~* Willing to use accepted method of contraception during the course of the study~* Negative pregnancy test (females)~* Written informed consent~Exclusion Criteria:~* Chemotherapy or radiotherapy within 4-6 weeks of the start of treatment (depending on the therapy)~* Investigational drug within 30 days of the start of treatment~* Uncontrolled intercurrent illness such as infection or cardiovascular disease~* Pregnant or breastfeeding women~* Subjects known to be HIV positive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-PRP protocol refraction, fluorescein angiography, and optical coherence tomography AND 7-14 day post-PRP OCT~* Ability to provide written informed consent and comply with study assessments for the full duration of the study~* Age 21 years or older~* Previously untreated PDR patients with high risk characteristics who develop edema within 7-14 days post PRP therapy. This edema, determined by a masked investigator, will be characterized as either increased foveal thickness (\>10% increase from pre-PRP foveal thickness), and/or increased macular volume on OCT (\>10% increase from pre-PRP macular volume).~Exclusion Criteria:~* Pregnancy (positive pregnancy test) prior to enrollment in the study~* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.~* Participation in another simultaneous medical investigation or trial~* Pre-PRP clinically significant diabetic macular edema (CSME) that would make the patient eligible for macular laser prior to PRP~* Neovascularization of the iris or neovascular glaucoma~* Increased central foveal thickness for any other reason~* Concurrent macular diseases that could confound the results of this study~* Prior vitrectomy in the study eye~* Prior treatment with intravitreal injection including pegaptanib sodium, ranibizumab, bevacizumab or triamcinolone acetonide

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab (Type: EXPERIMENTAL): Ranibizumab is being used off-label to test the safety and efficacy of its use in Diabetic Macular Edema post panretinal photocoagulation. Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of SC-007 in Subjects With Advanced Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed advanced metastatic or unresectable advanced colorectal cancer (CRC) or gastric cancer that is relapsed, refractory, or progressive after:~* CRC: at least 2 prior systemic regimens in the metastatic setting, and as appropriate in patients whose tumors are microsatellite instability-high (MSI-H), pembrolizumab as well.~* Gastric cancer (including gastric and EGJ cancers): at least 2 prior systemic regimens in adjuvant, advanced, or metastatic setting and, as appropriate, a human epidermal growth factor receptor 2 (HER2) targeted agent.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Adequate hematologic, hepatic, and renal function.~Exclusion Criteria:~* Any significant medical condition that, in the opinion of the investigator or sponsor, may place the participant at undue risk from the study.~* Has electrocardiogram (ECG) abnormalities that make QT interval corrected (QTc) evaluation difficult.~* Prior exposure to a pyrrolobenzodiazepine or indolinobenzodiazepine based drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- SC-007 (Type: EXPERIMENTAL): SC-007 intravenous (IV) (various doses and dose regimens)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Immediate Implant Breast Reconstruction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed breast carcinoma~* Patients planned for mastectomy with immediate single stage breast reconstruction using an acellular dermal matrix (Strattice™, LifeCell Corporation)~* Patients planned to receive postoperative chest wall irradiation~* Age ≥ 18 years old~* WHO performance status 0-1~* Affiliation to a social security system~* Informed consent signed prior any study specific procedures~Exclusion Criteria:~* Inflammatory breast cancer~* Tumors with extensive involvement of the skin~* Use of tissue expander~* Indication of postoperative chemotherapy~* Patients planned for bilateral mastectomy~* History of previously treated ipsilateral breast carcinoma~* Usual contraindications for ADM~* Medical debility precluding surgical treatment~* Psychological, social, geographical disorders or any other condition that would preclude study compliance (treatment modalities and study follow-up).~* Pregnancy or breast feeding~* Inability to attend or comply with interventions or follow-up scheduling, disability or difficulty preventing a proper understanding of trial instructions~* Legal inability or restricted legal ability

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- immediate implant breast reconstruction (Type: EXPERIMENTAL): immediate implant breast reconstruction

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Daylight on Patients With Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with an acute myocardial infarction~* Healthy volunteers~* Must speak and understand English~Exclusion Criteria:~* Patients with an acute myocardial infarction but are too sick, e.g. severe symptoms, chest pain, generally unstable, etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Exposed to Day light (Type: EXPERIMENTAL): Patients with myocardial infarction (MI): This group will be enrolled on the day of their MI. A blood draw will be performed before any light therapy. The patients will then receive a light box (Square One Wake Up Light NatureBright 10,000 LUX) that they shall use every morning from 8.30-9.00 AM for the next 2 weeks. At the conclusion of the two weeks another blood sample will be drawn.
- Exposed to Room light (Type: SHAM_COMPARATOR): Patients with myocardial infarction (MI): This group will be enrolled on the day of their MI and will only be exposed to room light. They will have blood drawn on the day of enrollment and then at 2 weeks after the MI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study With OPTIVATE® in People With Von Willebrand Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Have given written informed consent.~2. Be aged 12 years or older.~3. Have severe VWD (VWF:RCo \<20%) of known type. Severity will be confirmed by a current VWF:RCo result of \<20%.~4. Be known or expected to require a concentrate for management of VWD.~5. Must have had at least one bleed in the last 12 months which required treatment with a FVIII and VWF concentrate.~6. Have a known lack of, or poor response to, DDAVP.~7. Have a prothrombin time (PT) of not more than 3 seconds above the upper limit of the reference range.~8. At the Baseline Visit (Visit 1), patients must have had at least 5 days since their last infusion of replacement factor concentrate or DDAVP.~9. Female patients of child-bearing potential must have a negative result on a human chorionic gonadotropin-based pregnancy test. If a female patient is or becomes sexually active, she must practice contraception by using a method of proven reliability for the duration of the study. Female patients must not be lactating.~Exclusion Criteria:~1. Have a history of inhibitor development to VWF or FVIII or a positive result at screening.~2. Actively bleeding (Note: the patient can enter the study once the bleed is controlled).~3. Presence of major systemic illnesses: renal disease, liver disease, or neurological or psychiatric disease which would compromise the outcome of the study in the opinion of the investigator.~4. Known or suspected hypersensitivity to investigational medicinal product (IMP) or its excipients.~5. Have a recent history of alcohol or drug abuse.~6. Administration of a new chemical entity within the 4 months preceding enrolment.~7. Participation in any other clinical study in which investigational or marketed drugs were employed in the 30 days preceding enrolment into this study, with the exception of the BPL clinical study Protocol 8VWF03.~8. In the opinion of the investigator, the patient is unlikely to comply with the study protocol.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Eosinophilic Esophagitis Clinical Therapy Comparison Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Signed written informed consent and assent if applicable prior to performing any study specific procedure.~2. Male or female subjects aged 3-17 years old.~3. Diagnosis of EoE within 2 months of enrollment (greater than or equal to 15 eosinophils per high powered field in both proximal or distal esophageal specimens).~4. Subjects who have failed at least a two month trial of proton pump inhibitor.~5. A female subject of childbearing potential who is or may become sexually active agrees to routinely use contraception from the time of signing informed consent and assent until 30 days from end of study.~6. Positive allergy testing on prick and/or patch testing.~Exclusion Criteria~1. Subjects who are responsive to at least a two month trial of a proton pump inhibitor.~2. Diagnosis of Inflammatory Bowel Disease or static encephalopathy.~3. Prior abdominal surgery and other organ disorder not including atopic diseases.~4. Previous esophageal surgical procedure.~5. Previous esophageal congenital disorders such as tracheal esophageal fistula and esophageal atresia.~6. Positive for pregnancy.~7. Previous therapy within 6 weeks with oral or swallowed steroids or strict dietary elimination of major allergens~8. Presence of increased eosinophils in the stomach, small intestine, large intestine, and colon based on Debrosse et al.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Positive for food allergy: Group A (Type: ACTIVE_COMPARATOR): Oral Budesonide
- Positive for food allergy: Group B (Type: ACTIVE_COMPARATOR): Elimination diet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ClinicCompanion. Compared to the Use of a Goniometer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* new or established clinic patients from PI's medical practice at Aurora St. Luke's Medical Center~* 18 years of age and older~Exclusion Criteria:~* no use of limbs~* amputees

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of JNJ-38518168 in Adult Participants With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants diagnosed with rheumatoid arthritis (RA) according to the revised 1987 criteria of the ARA (Arnett et al, 1988) for at least 6 months at Screening~* Participants who have been treated with and tolerated methotrexate (MTX) treatment at dosages from 7.5 to 25 milligram (mg) per week inclusive, for a minimum of 4 months before Screening~* Participants if using non-steroidal anti-inflammatory drugs (NSAIDs) or other analgesics (drug used to control pain) regularly for RA, participants must have been on a stable dose for at least 2 weeks before the first dose of study medication~* Participants if using oral corticosteroids (compounds, usually hormonal, taken orally \[by mouth\] in order to block ovulation \[discharge of an egg from the ovary\] and prevent the occurrence of pregnancy \[carrying an unborn baby\]), must be on a stable dose of less than or equal to 10 mg per day of prednisone or another oral corticosteroid for at least 4 weeks before the first dose of study medication and continue with the same dose throughout the study. If not using corticosteroids at study initiation, the participant must have not received any oral corticosteroids for at least 4 weeks before the first dose of study medication~* Participants currently treated with folic acid at a minimum dose of 5 mg per week~Exclusion Criteria:~* Participants having inflammatory disease other than RA~* Participant who have used any of the following medications: D-penicillamine, hydroxychloroquine, chloroquine, oral or parenteral gold salts, sulfasalazine, leflunomide, azathioprine, cyclosporine, tacrolimus, and mycophenolatemofetil~* Participant who have received intra-articular, intramuscular (into the muscle), or intravenous (into the vein) corticosteroids, including adrenocorticotropic hormone (hormone made by the brain that activates the adrenal glands) within 4 weeks before the first dose of the study medication~* Participants who have been treated with any other investigational drug or medical device within 4 weeks or 5 half-lives of the drug, whichever is longer before the first dose of study medication~* Participants who have undergone surgical treatments for RA including synoviectomy (surgical removal of a part of the synovial membrane of a joint) and arthroplasty (surgery to fix a joint) within 3 months before the first dose of study medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- JNJ-38518168 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Naltrexone Implants as Relapse Prevention

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* soon to complete inpatient treatment for opioid addiction~* living in southern Norway~Exclusion Criteria:~* psychosis / major depression, currently not treated~* pregnancy~* liver enzymes: ASAT or ALAT \> threefold above upper boundary~* maintenance treatment with methadone or buprenorphine

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues